Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Tutkimus DISC-0974:stä osallistujilla, joilla on myelofibroosi ja anemia

keskiviikko 21. lokakuuta 2026 päivittänyt: Disc Medicine, Inc

Vaiheen 1b/2a avoin tutkimus DISC-0974:n turvallisuuden, siedettävyyden, farmakokinetiikan ja farmakodynamiikan arvioimiseksi potilailla, joilla on myelofibroosi ja anemia

This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

150

Vaihe

  • Vaihe 2
  • Vaihe 1

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

  • Australia
      • Nedlands, Australia, 6009
      • Saint Albans, Australia, 3021
        • Rekrytointi
        • Western Health
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
        • Päätutkija:
          • William Renwick, MBBS
      • Sydney, Australia, 2010
      • West Perth, Australia, 6005
        • Rekrytointi
        • Perth Blood Institute
        • Ottaa yhteyttä:
        • Päätutkija:
          • Ross Baker, MBBS, BMedSc, FRACP, FACP
  • Yhdysvallat
    • Arizona
      • Gilbert, Arizona, Yhdysvallat, 85234
        • Rekrytointi
        • Banner MD Anderson
        • Ottaa yhteyttä:
        • Päätutkija:
          • Mark Faber, DO
    • California
      • Duarte, California, Yhdysvallat, 91010
        • Rekrytointi
        • City of Hope - Duarte
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
        • Päätutkija:
          • Idoroenyi Amanam, MD
      • Irvine, California, Yhdysvallat, 92618
        • Rekrytointi
        • City of Hope - Lennar
        • Päätutkija:
          • Idoroenyi Amanam, MD
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
      • Los Angeles, California, Yhdysvallat, 90095
        • Rekrytointi
        • UCLA
        • Päätutkija:
          • Wanxing Chai-Ho, MD
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
      • San Francisco, California, Yhdysvallat, 94143
        • Rekrytointi
        • University of California, San Francisco
        • Päätutkija:
          • Jerry Lee, MD, MS
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
    • Colorado
      • Aurora, Colorado, Yhdysvallat, 80045
        • Rekrytointi
        • University of Colorado Anschutz Medical Campus
        • Ottaa yhteyttä:
        • Päätutkija:
          • Brandon McMahon, MD
    • Florida
      • Jacksonville, Florida, Yhdysvallat, 32224
        • Rekrytointi
        • Mayo Clinic Jacksonville
        • Päätutkija:
          • James Foran, MD
        • Ottaa yhteyttä:
      • Miami, Florida, Yhdysvallat, 33136
        • Rekrytointi
        • Sylvester Cancer Center - U Miami
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
        • Päätutkija:
          • Sangeetha Venugopal, MD, MS
      • Tampa, Florida, Yhdysvallat, 33612
        • Rekrytointi
        • Moffitt Cancer Center
        • Päätutkija:
          • Andrew Kuykendall, MD
        • Ottaa yhteyttä:
    • Georgia
      • Atlanta, Georgia, Yhdysvallat, 30322
    • Illinois
      • Rolling Meadows, Illinois, Yhdysvallat, 60008
    • Iowa
      • Iowa City, Iowa, Yhdysvallat, 52242
        • Rekrytointi
        • University of Iowa
        • Ottaa yhteyttä:
        • Päätutkija:
          • Meredith Schaffner, DO
    • Michigan
      • Ann Arbor, Michigan, Yhdysvallat, 48109
        • Rekrytointi
        • University of Michigan
        • Ottaa yhteyttä:
        • Päätutkija:
          • Moshe Talpaz, MD
    • Minnesota
      • Rochester, Minnesota, Yhdysvallat, 55905
        • Rekrytointi
        • Mayo Clinic Rochester
        • Päätutkija:
          • Naseema Gangat, MBBS
        • Ottaa yhteyttä:
    • Missouri
      • St Louis, Missouri, Yhdysvallat, 63110
        • Rekrytointi
        • Washington University St.Louis
        • Ottaa yhteyttä:
        • Päätutkija:
          • Amy Zhou, MD
    • New Jersey
      • East Brunswick, New Jersey, Yhdysvallat, 08816
    • New York
      • New York, New York, Yhdysvallat, 10029
        • Rekrytointi
        • Icahn School of Medicine at Mount Sinai
        • Päätutkija:
          • John Mascarenhas, MD
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
      • New York, New York, Yhdysvallat, 10021
        • Rekrytointi
        • Memorial Sloan Kettering Cancer Center
        • Päätutkija:
          • Prioty Islam, MD, MSc
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
      • New York, New York, Yhdysvallat, 10467
        • Rekrytointi
        • Montefiore
        • Päätutkija:
          • Swati Goel, MD
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
    • North Carolina
      • Winston-Salem, North Carolina, Yhdysvallat, 27157
        • Rekrytointi
        • Atrium Health Wake Forest Baptist
        • Ottaa yhteyttä:
        • Päätutkija:
          • Anne Wofford, MD
    • Ohio
      • Canton, Ohio, Yhdysvallat, 44718
        • Lopetettu
        • Gabrail Cancer Center Research
      • Cleveland, Ohio, Yhdysvallat, 44195
        • Rekrytointi
        • Cleveland Clinic
        • Päätutkija:
          • Aaron Gerds, MD
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
      • Columbus, Ohio, Yhdysvallat, 43201
        • Rekrytointi
        • The Ohio State University
        • Päätutkija:
          • Shivani Handa, MD
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
      • Maumee, Ohio, Yhdysvallat, 43537
        • Rekrytointi
        • Taylor Cancer Research Center
        • Päätutkija:
          • John Nemunaitis, MD
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
    • Oregon
      • Portland, Oregon, Yhdysvallat, 97239
        • Rekrytointi
        • Oregon Health and Science University
        • Ottaa yhteyttä:
        • Päätutkija:
          • Ronan Swords, MD, PhD
    • Pennsylvania
      • Gettysburg, Pennsylvania, Yhdysvallat, 17325
        • Peruutettu
        • Sargon Research - Pennsylvania Cancer Specialists and Research Center
      • Philadelphia, Pennsylvania, Yhdysvallat, 19104
    • Texas
      • Houston, Texas, Yhdysvallat, 77030
        • Rekrytointi
        • MD Anderson
        • Päätutkija:
          • Prithviraj Bose, MD
        • Ottaa yhteyttä:
      • Temple, Texas, Yhdysvallat, 76508
    • Washington
      • Seattle, Washington, Yhdysvallat, 98109
        • Rekrytointi
        • University of Washington
        • Päätutkija:
          • Anna Halpern, MD
        • Ottaa yhteyttä:
    • Wisconsin
      • Milwaukee, Wisconsin, Yhdysvallat, 53226
        • Rekrytointi
        • Medical College of Wisconsin
        • Päätutkija:
          • Laura Michaelis, MD
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria for Participants with MF and Anemia:

Participants are eligible for the study if all of the following criteria apply:

  1. Age 18 years or older at the time of signing the informed consent form (ICF).

  2. For Phase 1b: Dynamic International Prognostic Scoring System (DIPSS) score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to World Health Organization (WHO) 2016 criteria.

    For Phase 2: In addition to the criteria above, DIPSS score of ≥2 (intermediate 1 risk) may also be included.

  3. Washout of at least 28 days prior to Screening of the following treatments:

    1. Androgens
    2. EPO
    3. Cladribine
    4. Immunomodulators (lenalidomide, thalidomide)
    5. Luspatercept/sotatercept
    6. Systemic corticosteroids are permitted for non-hematological conditions if stable or decreasing dose for ≥28 days prior to Screening and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening.

    Screening can begin before the 28 day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.

  4. Anemia:

    For Phase 1b: Hgb <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb <10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD cohort. The baseline Hgb value for these participants is the lowest Hgb level during the 84 days prior to Screening, or RBC transfusion dependence, defined as an RBC transfusion frequency of ≥6 units PRBC over the 84 days immediately prior to Screening. There must not be any consecutive 42-day period without an RBC transfusion in the 84-day period, and the last transfusion must be within 28 days prior to Screening.

    For Phase 2:

    TD high transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening TD low transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening nTD Cohort: Non-transfusion dependence, baseline Hgb <10 g/dL as defined on ≥3 assessments over 84 days prior to Screening, without RBC transfusion

  5. Stable dosing of MF-directed therapy:

    1. Hydroxyurea, or, if taking any other treatment for MF, stable for at least 28 days prior to Screening.
    2. Interferon alpha stable dosing for at least 12 weeks prior to Screening.
    3. JAK inhibitors require 12 weeks of stable dosing prior to Screening. For the TD high, TD low, and nTD cohorts, JAK inhibitors allowed include momelotinib, pacritinib, fedratinib, and ruxolitinib.
    4. If the participant discontinues JAK inhibitor (including momelotinib/pacritinib/ruxolitinib/fedratinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required.

  6. Eastern Cooperative Oncology Group (ECOG) performance score ≤2.

  7. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening.

  8. TSAT <75% (local lab acceptable) at or within 2 weeks of Screening.

  9. Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review. Required for TD high participants only.

  10. Serum ferritin ≥50 µg/L at Screening.

  11. Platelet count ≥25,000/µL and <1,000,000/µL; neutrophils ≥1,000/µL; and total white blood cell (WBC) count <50,000/µL at Screening.

  12. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.

  13. Aspartate aminotransferase (AST) and ALT <3.0x upper limit of normal (ULN) at Screening.

  14. Direct bilirubin <2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor.

  15. If male with female sexual partner(s) of childbearing potential, agrees to use 1 of the following highly effective methods of contraception during the study and for at least 8 weeks after the last study drug dose:

    1. Stable hormonal contraceptive (≥3 months; female partner)
    2. Intrauterine device in place for at least 3 months (female partner)
    3. Surgically sterile hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)
    4. Confirmed successful vasectomy

  16. If female, then EITHER postmenopausal (defined as 12 months of spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels >40 mIU/ml, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy), surgically sterile, OR agreeable to use 1 of the following highly effective contraception methods (listed below) on Day 1 (or earlier) and for at least 8 weeks after the last dose of study drug:

    1. Stable hormonal contraceptive (≥3 months)
    2. Intrauterine device in place for at least 3 months
    3. Tubal ligation or single male partner with vasectomy

  17. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).

  18. Able to understand the study aims, procedures, and requirements, and provide written informed consent.

  19. Able to comply with all study procedures.

Inclusion Criteria for Exploratory Cohort of Participants with MDS and Anemia:

Participants are eligible for the MDS exploratory cohort if all of the following criteria apply:

  1. Age 18 years or older at the time of signing the ICF.

  2. Molecular International Prognostic Scoring System (IPSS-M) classification of very low, low, or intermediate (ie, lower risk) MDS-ringed sideroblasts (RS) negative, MDS/MPN with ringed sideroblasts and thrombocytosis (RS-T), Chronic Myelomonocytic Leukemia (CMML), Atypical Chronic Myeloid Leukemia (aCML), or Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN-U) as confirmed in the most recent local bone marrow biopsy report according to WHO criteria.

  3. Washout of at least 28 days is required for prior anemia/neutropenia-directed therapies, including:

    1. Androgens
    2. EPO-stimulating agents
    3. Luspatercept
    4. Sotatercept (ACE-011)
    5. Imetelstat
    6. Granulocyte colony-stimulating factor (G CSF) OR granulocyte-macrophage CSF (GM CSF).
    7. Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening) Screening can begin before the 28-day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.

  4. Anemia:

    1. Baseline Hgb of <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb <10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening
    2. Medical history of ≤24 units of PRBC for MDS and anemia

  5. ECOG performance score ≤2

  6. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening

  7. TSAT <75% (local lab acceptable) at or within 2 weeks of Screening

  8. Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review

  9. Serum ferritin ≥50 μg/L at Screening

  10. Platelet count ≥25,000/μL and <1,000,000/μL, and total WBC count <50,000/μL at Screening or otherwise approved by Sponsor.

  11. eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula

  12. AST and ALT <3x ULN at Screening

  13. Direct bilirubin <2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis.

  14. If male with female sexual partner(s) of childbearing potential, agrees to use 1 of the following highly effective methods of contraception during the study and for at least 8 weeks after the last study drug dose:

    1. Stable hormonal contraceptive (≥3 months; female partner)
    2. Intrauterine device in place for at least 3 months (female partner)
    3. Surgically sterile hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)
    4. Confirmed successful vasectomy

  15. If female, then EITHER postmenopausal (defined as 12 months of spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/ml, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy), surgically sterile, OR agreeable to use 1 of the following highly effective contraception methods (listed below) on Day 1 (or earlier) and for at least 8 weeks after the last dose of study drug:

    1. Stable hormonal contraceptive (≥3 months)
    2. Intrauterine device in place for at least 3 months
    3. Tubal ligation or single male partner with vasectomy

  16. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).

  17. Able to understand the study aims, procedures, and requirements, and provide written informed consent.

  18. Able to comply with all study procedures.

Exclusion Criteria for Participants with MF and Anemia:

Participants are excluded from the study if any of the following criteria apply:

Medical History, Participants with MF and Anemia

  1. Hereditary hemochromatosis

  2. Hemoglobinopathy or intrinsic RBC defect associated with anemia

  3. Total splenectomy

  4. Hematopoietic cell transplant within the past 2 years, or graft vs host disease requiring immunosuppression

  5. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding

  6. Active immune-mediated hemolytic anemia

  7. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening

  8. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery

  9. Malignancy within the past 3 years, other than primary MF, post ET, or post PV MF. The following history or concurrent conditions are allowed:

    1. basal or squamous cell carcinoma of the skin
    2. carcinoma in situ of the cervix or the breast
    3. histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement

  10. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 3 months prior to Screening

  11. Known allergic reaction to any study drug excipient

  12. A history of anti-drug antibody formation

  13. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction <35%

  14. Hepatitis B or C, or human immunodeficiency virus (HIV) with detectable viral load

  15. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)

    Treatment History, Participants with MF and Anemia

  16. Iron chelation therapy in the 28 days prior to Screening

  17. Change in anticoagulant therapy regimen within 8 weeks prior to Screening

    Laboratory Exclusions, Participants with MF and Anemia

  18. Peripheral blood myeloblasts ≥10% of WBC differential at most recent evaluation prior to Screening

  19. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening

    Miscellaneous, Participants with MF and Anemia

  20. Pregnant or lactating

  21. Condition or concomitant medication that would confound the ability to interpret study data

  22. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study

  23. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening

Exclusion Criteria for Exploratory Cohort of Participants with MDS and Anemia:

Participants are excluded from the MDS exploratory cohort if any of the following criteria apply:

Medical History, Participants with MDS and Anemia

  1. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation from other diseases

  2. Peripheral blasts ≥5%

  3. Current treatment with hypomethylating agent or other acute myeloid leukemia (AML)-like combination chemotherapy or planned use within 6 months after Screening

  4. Prior treatment with >3 anemia-directed therapies (unless otherwise approved by Sponsor) including:

    1. Luspatercept
    2. Sotatercept (ACE-011)
    3. EPO-stimulating agent
    4. Imetelstat

  5. Hereditary hemochromatosis

  6. Hemoglobinopathy or intrinsic RBC defect associated with anemia

  7. Total splenectomy

  8. Hematopoietic cell transplant within the past 10 years

  9. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding

  10. Active immune-mediated hemolytic anemia

  11. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening

  12. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery

  13. Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts. The following history or concurrent conditions are allowed:

    1. Basal or squamous cell carcinoma of the skin
    2. Carcinoma in situ of the cervix or the breast
    3. Histologic finding of prostate cancer (T1a or T1b using the TNM clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement

  14. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 6 months prior to Screening

  15. Known allergic reaction to any study drug excipient

  16. A history of antidrug antibody formation

  17. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction <35%

  18. Active hepatitis B or C, or HIV with detectable viral load

  19. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)

    Treatment History, Participants with MDS and Anemia

  20. Iron chelation therapy in the 28 days prior to Screening

  21. Change in anticoagulant therapy regimen within 8 weeks prior to Screening

    Laboratory Exclusions, Participants with MDS and Anemia

  22. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening

    Miscellaneous, Participants with MDS and Anemia

  23. Pregnant or lactating

  24. Condition or concomitant medication that would confound the ability to interpret study data

  25. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study

  26. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Peräkkäinen tehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Phase 1b: Dose Escalation

In the Phase 1b (dose-escalation) portion of the study, DISC-0974 will be administered subcutaneously every 4 weeks.
Lääke: DISC-0974

DISC-0974 is administered subcutaneously.
Kokeellinen: Phase 2: Expansion

In the Phase 2 (expansion) portion of the study, DISC-0974 will be administered subcutaneously every 4 weeks.
Lääke: DISC-0974

DISC-0974 is administered subcutaneously.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Safety and Tolerability of DISC-0974 (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Assessed by treatment-emergent adverse events
From Day 1 to the end of treatment on Day 169
Safety and Tolerability of DISC-0974 (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Assessed by vital signs through blood pressure (mmHg), heart rate (bpm), respiration rate (breaths/min), and temperature (°C)
From Day 1 to the end of treatment on Day 169
Safety and Tolerability of DISC-0974 (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Assessed by physical examinations
From Day 1 to the end of treatment on Day 169
Safety and Tolerability of DISC-0974 (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Assessed by electrocardiogram (ECG) parameters: heart rate, PR interval, QRS duration, QRS axis, QT interval, and QTcF interval)
From Day 1 to the end of treatment on Day 169
Safety and Tolerability of DISC-0974 assessed through blood testing (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

The blood testing will include a hematology panel, blood chemistry panel, serology/virology panel, biomarker assessments, PK assessments, and Anti-Drug Antibodies
From Day 1 to the end of treatment on Day 169
Safety and Tolerability of DISC-0974 assessed through urine testing (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

The urine testing will include a urinalysis
From Day 1 to the end of treatment on Day 169
Transfusion-dependent (TD) high cohort: transfusion independence (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Defined as the absence of packed red blood cell (PRBC) transfusions over any rolling 12-week interval during the treatment period with a minimum hemoglobin (Hgb) of 7 g/dL. Participants meeting this criterion will be considered to have a major response to treatment.
From Day 1 to the end of treatment on Day 169
TD low cohort: transfusion independence (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Defined as the absence of PRBC transfusions over any rolling 16-week interval during the treatment period with a minimum Hgb of 7 g/dL. Participants meeting this criterion will be considered to have a major response to treatment.
From Day 1 to the end of treatment on Day 169
Non-transfusion-dependent (nTD) cohort: anemia response (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Defined as the composite of the absence of transfusions over any rolling 12-week period and a concomitant mean Hgb increase of ≥1.5 g/dL over baseline. Participants meeting this criterion will be considered to have a major response to treatment.
From Day 1 to the end of treatment on Day 169

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
TD high and TD low participants will be evaluated for absence of PRBC transfusions for any rolling 12-week interval during the treatment period (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
TD high participants will be evaluated for absence of PRBC transfusions with minimum Hgb of 7 g/dL during any rolling 12-week interval during the treatment period (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
TD low participants will be evaluated for absence of PRBC transfusions with minimum Hgb of 7 g/dL during any rolling 16-week interval during the treatment period (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
nTD participants will be evaluated for ≥1.5 g/dL increase from baseline Hgb levels during the treatment period (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
nTD participants will be evaluated for the composite of the absence of transfusions over any rolling 12-week period and a concomitant mean Hgb increase of ≥1.5 g/dL over baseline (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Incidence of clinically abnormal vital signs following repeated DISC-0974 SC doses in participants with myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MPN) without excess blasts and anemia (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Incidence of clinically abnormal physical exam following repeated DISC-0974 SC doses in participants with myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MPN) without excess blasts and anemia (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Incidence of clinically abnormal electrocardiograms (ECGs) following repeated DISC-0974 SC doses in participants with myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MPN) without excess blasts and anemia (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Incidence of abnormal laboratory test results following repeated DISC-0974 SC doses in participants with myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MPN) without excess blasts and anemia (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
PD markers of mechanism engagement, including exploratory cohorts assessed through serum iron levels (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
PD markers of mechanism engagement, including exploratory cohorts assessed through TSAT levels (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
PD markers of mechanism engagement, including exploratory cohorts assessed through Ferritin levels (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
PD markers of mechanism engagement, including exploratory cohorts assessed through Transferrin levels (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
PD markers of mechanism engagement, including exploratory cohorts assessed through Serum-hepcidin-25 levels (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Hematologic Parameters assessed through Reticulocyte count (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Hematologic Parameters assessed through Hemoglobin levels (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Hematologic Parameters assessed through Reticulocyte Hemoglobin (CHr) (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Hematologic Parameters assessed through Red Blood Cell Count (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Rate of RBC transfusions per participant month during the treatment period for each cohort (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
The number of units of RBC transfusions per participant month during the treatment period for each cohort (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
nTD participants will be evaluated for longest duration of mean Hgb increase of ≥1.5 g/dL from baseline during the treatment period (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Mean change in Hgb over 12-week treatment periods will be evaluated for all cohorts (nTD, TD low, and TD high) (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Maximum duration of RBC-transfusion-independent response for TD participants (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Proportion of participants that require dose escalation in each cohort (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Proportion of participants that improve Functional Assessment of Cancer Therapy-Anemia (FACT-An) subscale by at least 3 points in each cohort during the treatment period (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Mean hemoglobin increase of ≥1.5 g/dL over any rolling 12-week interval and an increase in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue of 3 points by the end of study (EOS) for nTD participants (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
TD high cohort will be evaluated for absence of packed red blood cell (PRBC) transfusions a terminal 12-week interval during the treatment period with a minimum hemoglobin (Hgb) of 7 g/dL (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
TD low cohort: will be evaluated for the absence of PRBC transfusions a terminal 16-week interval during the treatment period with a minimum Hgb of 7 g/dL (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169
From Day 1 to the end of treatment on Day 169
Anemia response defined per IWG-MRT 2006 criteria (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Response in nTD participants is defined as ≥2.0 g/dL increase from baseline in Hgb levels. Response in TD participants requires absence of PRBC transfusions during any rolling 12-week period during the treatment period, capped by an Hgb level of ≥8.5 g/dL.
From Day 1 to the end of treatment on Day 169
Incidence of TEAEs following repeated DISC-0974 SC doses in participants with myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MPN) without excess blasts (collectively referred to as MDS) and anemia (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Proportion of participants with treatment-emergent adverse events
From Day 1 to the end of treatment on Day 169
Pharmacokinetic data of DISC-0974 following repeated SC doses in participants with myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MPN) without excess blasts and anemia (Phase 1b only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Pharmacokinetic parameters include DISC-0974 pre-dose concentrations at different visits
From Day 1 to the end of treatment on Day 169
Proportion of participants achieving a mean Hgb increase ≥1 g/dL or ≥2 g/dL from baseline over any rolling 12-week period in absence of PRBC transfusions in each cohort (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Participants who are nTD and achieve a mean Hgb increase ≥1 g/dL from baseline over any rolling 12-week period in the absence of transfusion will be considered to have a minor response to treatment.
From Day 1 to the end of treatment on Day 169
Transfusion-dependent cohorts will be evaluated for proportion of participants who reduce their transfusion requirement by ≥50%, as compared to baseline, over any rolling 12-week period during treatment. (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Participants who are TD and achieve a reduction in transfusion requirement ≥50% as compared to baseline over any rolling 12-week period during treatment will be considered to have a minor response to treatment.
From Day 1 to the end of treatment on Day 169
Non-transfusion-dependent (nTD) cohort will be evaluated for anemia response (Phase 1b and 2)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Defined as the composite of the absence of transfusions over any rolling 12-week period and a concomitant mean Hgb increase of ≥1.5 g/dL over baseline
From Day 1 to the end of treatment on Day 169
Safety and Tolerability of DISC-0974 (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Assessed by treatment-emergent adverse events
From Day 1 to the end of treatment on Day 169
Safety and Tolerability of DISC-0974 (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Assessed by vital signs through blood pressure (mmHg), heart rate (bpm), respiration rate (breaths/min), and temperature (°C)
From Day 1 to the end of treatment on Day 169
Safety and Tolerability of DISC-0974 (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Assessed by physical examinations
From Day 1 to the end of treatment on Day 169
Safety and Tolerability of DISC-0974 (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Assessed by electrocardiogram (ECG) parameters: heart rate, PR interval, QRS duration, QRS axis, QT interval, and QTcF interval)
From Day 1 to the end of treatment on Day 169
Safety and Tolerability of DISC-0974 assessed through blood testing (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

The blood testing will include a hematology panel, blood chemistry panel, serology/virology panel, biomarker assessments, PK assessments, and Anti-Drug Antibodies
From Day 1 to the end of treatment on Day 169
Safety and Tolerability of DISC-0974 assessed through urine testing (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

The urine testing will include a urinalysis
From Day 1 to the end of treatment on Day 169
Safety and tolerability of DISC-0974 following repeated SC doses in participants with MF receiving concomitant momelotinib or pacritinib therapy (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Assessed by treatment-emergent adverse events
From Day 1 to the end of treatment on Day 169
Safety and tolerability of DISC-0974 following repeated SC doses in participants with MF receiving concomitant momelotinib or pacritinib therapy (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Assessed by vital signs through blood pressure (mmHg), heart rate (bpm), respiration rate (breaths/min), and temperature (°C)
From Day 1 to the end of treatment on Day 169
Safety and tolerability of DISC-0974 following repeated SC doses in participants with MF receiving concomitant momelotinib or pacritinib therapy (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Assessed by physical examinations
From Day 1 to the end of treatment on Day 169
Safety and tolerability of DISC-0974 following repeated SC doses in participants with MF receiving concomitant momelotinib or pacritinib therapy (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Assessed by electrocardiogram (ECG) parameters: heart rate, PR interval, QRS duration, QRS axis, QT interval, and QTcF interval)
From Day 1 to the end of treatment on Day 169
Safety and tolerability of DISC-0974 following repeated SC doses in participants with MF receiving concomitant momelotinib or pacritinib therapy assessed through blood testing (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

The blood testing will include a hematology panel, blood chemistry panel, serology/virology panel, biomarker assessments, PK assessments, and Anti-Drug Antibodies
From Day 1 to the end of treatment on Day 169
Safety and tolerability of DISC-0974 following repeated SC doses in participants with MF receiving concomitant momelotinib or pacritinib therapy assessed through urine testing (Phase 2 only)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

The urine testing will include a urinalysis
From Day 1 to the end of treatment on Day 169

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Cmax (Phase 1b, 2, and Exploratory Cohorts)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Maximum drug concentration (observed). Will be determined from blood PK sampling if appropriate data are available
From Day 1 to the end of treatment on Day 169
Tmax (Phase 1b, 2, and Exploratory Cohorts)
Aikaikkuna: From Day 1 to the end of treatment on Day 169

Observed time of the maximum drug concentration. Will be determined from blood PK sampling if appropriate data are available
From Day 1 to the end of treatment on Day 169
AUC (Phase 1b, 2, and Exploratory Cohorts)
Aikaikkuna: From Day 0 to 29 days after the first dose

Area under the drug concentration-time curve calculated using linear trapezoidal summation from time zero to 29 days following the first dose. Will be determined from blood PK sampling if appropriate data are available.
From Day 0 to 29 days after the first dose

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Disc Medicine, Inc

Tutkijat

  • Opintojohtaja: Will Savage, MD PhD, Disc Medicine

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Maanantai 6. kesäkuuta 2022

Ensisijainen valmistuminen (Arvioitu)

Lauantai 1. toukokuuta 2027

Opintojen valmistuminen (Arvioitu)

Tiistai 1. kesäkuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 15. maaliskuuta 2022

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 1. huhtikuuta 2022

Ensimmäinen Lähetetty (Todellinen)

Maanantai 11. huhtikuuta 2022

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 22. lokakuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 21. lokakuuta 2026

Viimeksi vahvistettu

Maanantai 1. kesäkuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • DISC-0974-102

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa